Summary
The pharmacokinetics of valproic acid (VPA) have been studied during peritoneal dialysis in a uremic male epileptic child following a single 500 mg dose and after multiple doses over 5 months (700 mg daily) of valproic acid as the syrup. Serum level decline was biphasic in both instances with a terminal half-life of 27.2 h after the single dose and 10.2 h at steady-state. Total serum clearance was 0.0236 l/h/kg after the single dose and increased to 0.0408 l/h/kg after 5 months. Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies. Peritoneal dialysis for periods of 12 or 24 h removed an average of 4.5% of the VPA dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gugler R, von Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5: 67–83
Brewster D, Muir NC (1980) Valproate plasma protein binding in the uremic condition. Clin Pharmacol Ther 27: 76–82
Marbury TC, Lee CS, Bruni J, Buna J, Wilder BJ (1980) Hemodialysis of valproic acid in uremic patients. Dialysis Transplant 9: 961–964
Richens A (1976) Drug Interactions. In: Richens A (ed) Drug treatment of epilepsy. Henry Kingston, London, pp 105–117
Kober A, Olsson Y, Sjoholm I (1980) Binding of drugs to human serum albumin: xiv. The theoretical basis for the interaction between phenytoin and valproate. Molec Pharmacol 18: 237–242
Abbott FS, Burton R, Orr JM, Wladichuk D, Ferguson S, Sun T-H (1982) Valproic acid analysis in saliva and serum using selected ion monitoring of the tertiarybutyldimethylsilyl derivatives. J Chromatogr 227: 433–444
Sjoholm I, Kober A, Odor-Cederlof I, Borga O (1976) Protein binding of drugs in uremic and normal serum: The role of endogenous binding inhibitors. Biochem Pharmacol 25: 1205–1213
Gibaldi M, Perrier D (1975) Pharmacokinetics, Dekker, New York, pp 68
Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–671
Schapel GJ, Beran RG, Doecke CJ, O'Reilly WJ, Reece PA, Rischbieth RNC, Sanson LN, Stanley PE (1980) Pharmacokinetics of sodium valproate in epileptic patients. Prediction of maintenance dosage by single dose study. Eur J Clin Pharmacol 17: 71–77
Farrell K, Orr JM, Abbott FS, Ferguson S, Sheppard I, Godolphin WJ, Bruni J (1982) The effect of acetylsalicylic acid on free serum valproic acid levels and clearance in children. J Paediatr 101: 142–144
Schobben F, van der Kleijn E, Gabriels FJM (1975) Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol 8: 97–105
Orr JM, Abbott FS, Farrell K, Ferguson S, Godolphin WJ (1982) Interaction between valproic acid and ASA in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 31: 642–649
Patel I, Levy R (1979) Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 20: 85–90
Monks A, Richens A (1979) Serum protein binding of valproic acid and its displacement of palmitic acid in vitro. Br J Clin Pharmacol 8: 187–188
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Orr, J.M., Farrell, K., Abbott, F.S. et al. The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. Eur J Clin Pharmacol 24, 387–390 (1983). https://doi.org/10.1007/BF00610060
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00610060